Regression of Iris Neovascularization After Intravitreal Injection of Bevacizumab in Patients With Proliferative Diabetic Retinopathy - 18/08/11
, Hirokazu Sakaguchi, MD, Fumi Gomi, MD, Yasuo Tano, MD
Inquiries to Yusuke Oshima, MD, Department of Ophthalmology, Osaka University Medical School, 2-2 Yamadaoka, E-7, Suita, Osaka 565-0871, JapanRésumé |
Purpose |
To assess the short-term safety and efficacy of intravitreal injection of bevacizumab for iris neovascularization (INV).
Design |
Noncomparative, interventional case series.
Methods |
Intravitreal bevacizumab was injected in seven eyes of five patients with INV that was associated with proliferative diabetic retinopathy (PDR). The main outcome measurements were visual acuity, intraocular pressure (IOP), and regression of INV by fluorescein angiography before and one week, one month, and two months after injection.
Results |
Regression of INV was confirmed in all eyes (100%) from one week after injection. Repeated injections stabilized the recurrence (two eyes; 29%) that was observed two months after the initial injection. The visual acuity remained stable or improved, and the intraocular pressure was controlled in six eyes (86%) throughout the follow-up period. No inflammation or complications were observed.
Conclusions |
Intravitreal injection of bevacizumab may be an effective and safe alternative for patients with INV that is refractory to conventional treatments.
Le texte complet de cet article est disponible en PDF.| Supplemental Material available at AJO.com Supported in part by a Research Grant (16591751 [Y.O.]) from the Ministry of Education, Science and Culture, Tokyo, Japan. |
Vol 142 - N° 1
P. 155 - juillet 2006 Retour au numéro
Article précédent
- Fungal Keratitis Associated With Non-therapeutic Soft Contact Lenses
- Eduardo C. Alfonso, Darlene Miller, Jorge Cantu-Dibildox, Terrence P. O’Brien, Oliver D. Schein
- Intracameral Bevacizumab for Iris Rubeosis
- Salvatore Grisanti, Sabine Biester, Swaantje Peters, Olcay Tatar, Focke Ziemssen, Karl Ulrich Bartz-Schmidt, The Tuebingen Bevacizumab Study Group
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?